Remsima™ SC, the first subcutaneous infliximab, now approved in Canada for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD)1 The approval is based on results from the LIBERTY2,3 studi
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Ken Seitz, Nutrien’s President and Chief Executive Officer, will be speaking at the BMO Global Metals, Mining and Critical Minerals Conference on Tuesday
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Mark Thompson, Nutrien’s Executive Vice President and Chief Commercial Officer, and Mr. Jeff Tarsi, Nutrien’s Executive Vice President and President, G
Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as o
OTTAWA, Canada--(BUSINESS WIRE)--#ait--BioTalent Canada today announced the organizations who have distinguished themselves as Inclusion, Diversity, Equity, and Accessibility Leaders through the I.D.E.A.L. Bioscience Employer™ recognition program. The p
RP-1664 is a Potential First-in-Class, Selective, PLK4 InhibitorCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announce
-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company --SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Firefly Bio emerg
NASHVILLE, Tenn. & TORONTO--(BUSINESS WIRE)--$HROW--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing a
MONTREAL--(BUSINESS WIRE)--“It is with determination that the entire Aplantex team follows its game plan with discipline to become a leading supplier of high-value molecules to the pharmaceutical, cosmetics, and agri-food industries in the context of th
- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive design - Ended quarter with $25 million in cash and equivalents
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.